Industry news

08 May 2018

Syndax Pharmaceuticals Reports First Quarter 2018 Financial Results and Provides Clinical and Business Update

Syndax Pharmaceuticals, Inc.  ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today reported its financial results for the first quarter ended  March 31, 2018 . In addition, the Company provided a clinical and business update. As of  March 31, 2018 , Syndax had  $113.2 million  in cash, cash equivalents and short-term investments.

Pfizer wants you—to join its diverse scientists showcased in new ad

Beth Snyder Bulik / FiercePharma

Diversity is the star of Pfizer’s latest marketing push. In a new ad launching today, a mom wakes up to her child of a different race jumping on the bed, two men eat breakfast together and laugh as one sneaks the dog a bit of bacon, a woman wearing a hijab leaves her house, and a young woman with platinum blond hair and a nose ring listens to loud music while brushing her teeth.

Russian government approved operation model for product labeling system

GMP News

Prime Minister of the Russian Federation signed the Order No. 791-r of April 28, 2018, which approved the operation model for the system of labeling products by means of identification in the Russian Federation.

EAEU rules of Good Distribution Practice became effective on April 27

GMP News

EAEU rules of Good Distribution Practice (GDP) were adopted by the Decision of the Council of the Eurasian Economic Commission (EEC) No. 80 of November 3, 2016, while their entry into force was postponed for 18 months. The transition period allowed distributors and manufacturers of medicinal products to prepare for the enforcement of the new rules.

Russian scientists developed an innovative vaccine against herpes

GMP News

DNA vaccine against herpes developed by St. Petersburg Research Institute of High-Purity Biological Preparations of the Federal Biomedical Agency of Russia is much safer than the existing analogs which contain the weakened virus or its inactivated components.

The global CRO market reached $44.4 billion value in 2017

GMP News

According to report from The Business Research Company, the global market for clinical trial services to biopharmaceutical and medical device companies is forecast to grow at 12 per cent year on year to 2021. That is an acceleration from its rate of 10 per cent up to 2017 which raised its value to $44.4 billion.

02 May 2018

Marinus Pharmaceuticals Provides Business Update and First Quarter 2018 Financial Results

Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS) (“Marinus” or “Company”), a biopharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and neuropsychiatric disorders, today provided a business update on its clinical development activities and reported its financial results for the first quarter ended  March 31, 2018.

Russia will start producing powerful opioid analgesic from its own raw materials

GMP News

Russian Ministry of Health prepared a draft government decree to expand state quotas for manufacturing Remifentanil, a narcotic analgesic. The document proposes to amend the section “Narcotic Drugs” of the Annex to the Government Decree “On Approval of State Quotas for Annual Manufacturing, Storage and Importation (Exportation) of Narcotic Drugs and Psychotropic Substances.”

Still innovating, thanks: Most contest winners press ahead, and some even launch

Beth Snyder Bulik / FiercePharma

For the past seven years, Luminary Labs has run innovation challenges for healthcare and pharma companies, including Sanofi, Merck & Co. and Janssen, racking up a total of 17 large-scale contests that shelled out more than $5 million in prize money.

Pharma ads on the brain: DTC on lifestyle sites triggers a bigger emotional punch

Beth Snyder Bulik / FiercePharma

This is your brain on pharma ads. For a new neuroscience study from Condé Nast and Neuro-Insight, researchers actually hooked people’s brains up to sensors to measure neural activity and reactions to digital pharma ads.